[go: up one dir, main page]

IL155073A0 - Split enveloped virus preparation - Google Patents

Split enveloped virus preparation

Info

Publication number
IL155073A0
IL155073A0 IL15507301A IL15507301A IL155073A0 IL 155073 A0 IL155073 A0 IL 155073A0 IL 15507301 A IL15507301 A IL 15507301A IL 15507301 A IL15507301 A IL 15507301A IL 155073 A0 IL155073 A0 IL 155073A0
Authority
IL
Israel
Prior art keywords
enveloped virus
virus preparation
split enveloped
split
preparation
Prior art date
Application number
IL15507301A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0024088A external-priority patent/GB0024088D0/en
Priority claimed from GB0109288A external-priority patent/GB0109288D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL155073A0 publication Critical patent/IL155073A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18563Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661Methods of inactivation or attenuation
    • C12N2760/18663Methods of inactivation or attenuation by chemical treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15507301A 2000-10-02 2001-10-01 Split enveloped virus preparation IL155073A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0024088A GB0024088D0 (en) 2000-10-02 2000-10-02 Novel compounds
GB0109288A GB0109288D0 (en) 2001-04-12 2001-04-12 Novel compounds
PCT/EP2001/011328 WO2002028426A1 (en) 2000-10-02 2001-10-01 Split enveloped virus preparation

Publications (1)

Publication Number Publication Date
IL155073A0 true IL155073A0 (en) 2003-10-31

Family

ID=26245086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15507301A IL155073A0 (en) 2000-10-02 2001-10-01 Split enveloped virus preparation

Country Status (17)

Country Link
US (1) US20040028698A1 (es)
EP (1) EP1322329A1 (es)
JP (1) JP2004510747A (es)
KR (1) KR20030055275A (es)
CN (1) CN1253207C (es)
AR (1) AR030829A1 (es)
AU (2) AU2002215914B2 (es)
BR (1) BR0114392A (es)
CA (1) CA2423610A1 (es)
CZ (1) CZ2003930A3 (es)
HU (1) HUP0302636A3 (es)
IL (1) IL155073A0 (es)
MX (1) MXPA03002890A (es)
NO (1) NO20031484L (es)
NZ (1) NZ525076A (es)
PL (1) PL362964A1 (es)
WO (1) WO2002028426A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244946C (en) * 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
NZ525076A (en) * 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
CN1305526C (zh) * 2003-12-29 2007-03-21 薛平 乙型脑炎病毒裂解疫苗及其制备方法
MX2007010306A (es) * 2005-02-23 2007-09-26 Uab Research Foundation Vacunacion mejorada con alquil-glicosido.
US20090130127A1 (en) 2005-08-01 2009-05-21 Seiji Tokumoto Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration
ME00045B (me) * 2006-01-26 2010-10-10 Zoetis Services Llc Nove kompozicije glikolipidnog adjuvansa
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
RU2531510C2 (ru) 2008-12-09 2014-10-20 Новавакс, Инк. Модифицированные f протеины sv и способы их применения
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
US20130236496A1 (en) * 2010-06-29 2013-09-12 Universite De Laval Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response
PH12013502442A1 (en) * 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
EP3064218B1 (en) 2013-10-31 2019-06-19 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition
KR20160068972A (ko) * 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
KR102667355B1 (ko) 2015-09-03 2024-05-20 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
ES3028362T3 (en) 2017-07-24 2025-06-19 Novavax Inc Methods and compositions for treating respiratory disease
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
EP3775174A4 (en) * 2018-03-30 2022-07-06 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (rsv) vaccines
CN110665002B (zh) * 2019-10-29 2023-01-24 信阳市动物疫病预防控制中心 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法
CN113804593B (zh) * 2020-06-11 2024-05-24 北京科兴生物制品有限公司 一种裂解疫苗裂解效果的检测方法及应用
EP4175969A4 (en) * 2020-07-01 2024-07-24 Medimmune, LLC DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT
CN112190705A (zh) * 2020-09-25 2021-01-08 广州源博医药科技有限公司 一种rsv-sh亚单位疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1486557A (en) * 1973-10-18 1977-09-21 Flockhart & Co Process for the preparation of pyrogen-free sub-unit vaccine
DE2829089A1 (de) * 1977-07-13 1979-02-01 Sandoz Ag Subunit-vakzine
DE2750045A1 (de) * 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
KR20010042573A (ko) * 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US20020004046A1 (en) * 2000-05-03 2002-01-10 Johnson Leslie S. Combination therapy of respiratory diseases using antibodies
NZ525076A (en) * 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation

Also Published As

Publication number Publication date
PL362964A1 (en) 2004-11-02
BR0114392A (pt) 2003-09-02
NZ525076A (en) 2004-09-24
AU1591402A (en) 2002-04-15
WO2002028426A8 (en) 2002-06-06
US20040028698A1 (en) 2004-02-12
AU2002215914B2 (en) 2004-08-19
CZ2003930A3 (cs) 2003-08-13
NO20031484L (no) 2003-05-28
CN1477973A (zh) 2004-02-25
HUP0302636A3 (en) 2008-03-28
CA2423610A1 (en) 2002-04-11
NO20031484D0 (no) 2003-04-01
KR20030055275A (ko) 2003-07-02
JP2004510747A (ja) 2004-04-08
MXPA03002890A (es) 2004-12-03
EP1322329A1 (en) 2003-07-02
CN1253207C (zh) 2006-04-26
WO2002028426A1 (en) 2002-04-11
AR030829A1 (es) 2003-09-03
HUP0302636A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
HUP0302636A3 (en) Split enveloped virus preparation
PL362705A1 (en) Split enveloped virus preparation for intranasal delivery
GB2337755B (en) Virus vaccine
GB0020953D0 (en) Vaccine
HUP0301043A3 (en) Vaccine
IL150908A0 (en) Single phase gels and methods for the preparation thereof
AU8189501A (en) Vaccine composition
HUP0302117A3 (en) Vaccine composition
GB0020089D0 (en) Vaccine Composition
AU6269101A (en) Cosmetic preparation
GB0024200D0 (en) Component vaccine
GB0017720D0 (en) Modified virus
GB0014288D0 (en) Vaccine
GB0001475D0 (en) Virus strains
GB0014845D0 (en) Vaccine
GB0026334D0 (en) Vaccine
AU8252101A (en) Oct preparations
GB0025694D0 (en) Vaccine
GB9925432D0 (en) Virus preparation
GB0003082D0 (en) Vaccine
GB0006693D0 (en) Vaccine
GB0015722D0 (en) Vaccine
GB0027433D0 (en) Vaccine component
GB9925434D0 (en) Virus Preparation
GB0015935D0 (en) Vaccine